These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 23421897)

  • 41. Pharmacokinetics of budesonide and formoterol administered via 1 pressurized metered-dose inhaler in patients with asthma and COPD.
    Tronde A; Gillen M; Borgström L; Lötvall J; Ankerst J
    J Clin Pharmacol; 2008 Nov; 48(11):1300-8. PubMed ID: 18974284
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparison of the lung absorption of FK224 inhaled from a pressurized metered dose inhaler and a dry powder inhaler by healthy volunteers.
    Nakate T; Yoshida H; Ohike A; Tokunaga Y; Ibuki R; Kawashima Y
    Eur J Pharm Biopharm; 2003 Nov; 56(3):319-25. PubMed ID: 14602173
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pharmacokinetics and pharmacodynamics of fluticasone propionate and salmeterol delivered as a combination dry powder from a capsule-based inhaler and a multidose inhaler in asthma and COPD patients.
    Daley-Yates PT; Mehta R; Chan RH; Despa SX; Louey MD
    J Aerosol Med Pulm Drug Deliv; 2014 Aug; 27(4):279-89. PubMed ID: 24074143
    [TBL] [Abstract][Full Text] [Related]  

  • 44. In vivo-in vitro comparison of deposition in three mouth-throat models with Qvar and Turbuhaler inhalers.
    Zhang Y; Gilbertson K; Finlay WH
    J Aerosol Med; 2007; 20(3):227-35. PubMed ID: 17894531
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pharmacokinetic study for the establishment of bioequivalence of two inhalation treatments containing budesonide plus formoterol.
    Grekas N; Athanassiou K; Papataxiarchou K; Rizea Savu S; Silvestro L
    J Pharm Pharmacol; 2014 Dec; 66(12):1677-85. PubMed ID: 25109416
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pulmonary drug delivery from the Taifun dry powder inhaler is relatively independent of the patient's inspiratory effort.
    Pitcairn GR; Lankinen T; Seppälä OP; Newman SP
    J Aerosol Med; 2000; 13(2):97-104. PubMed ID: 11010599
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Studies of the human oropharyngeal airspaces using magnetic resonance imaging IV--the oropharyngeal retention effect for four inhalation delivery systems.
    Burnell PK; Asking L; Borgström L; Nichols SC; Olsson B; Prime D; Shrubb I
    J Aerosol Med; 2007; 20(3):269-81. PubMed ID: 17894534
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The clinical relevance of dry powder inhaler performance for drug delivery.
    Demoly P; Hagedoorn P; de Boer AH; Frijlink HW
    Respir Med; 2014 Aug; 108(8):1195-203. PubMed ID: 24929253
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Lung deposition of inhaled drugs increases with age.
    Onhøj J; Thorsson L; Bisgaard H
    Am J Respir Crit Care Med; 2000 Nov; 162(5):1819-22. PubMed ID: 11069819
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Factors guiding the choice of delivery device for inhaled corticosteroids in the long-term management of stable asthma and COPD: focus on budesonide.
    Thorsson L; Geller D
    Respir Med; 2005 Jul; 99(7):836-49. PubMed ID: 15939245
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comparative in vitro performance of three small-volume valved holding chambers with beclomethasone/formoterol pressurized metered dose inhaler.
    Goncalves TM; Alhanout K; Nicolay A; Dubus JC; de Santana DP; Andrieu V
    J Aerosol Med Pulm Drug Deliv; 2013 Aug; 26(4):223-7. PubMed ID: 23094686
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effect of Pressurized Metered Dose Inhaler Spray Characteristics and Particle Size Distribution on Drug Delivery Efficiency.
    Yousefi M; Inthavong K; Tu J
    J Aerosol Med Pulm Drug Deliv; 2017 Oct; 30(5):359-372. PubMed ID: 28463041
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Radiolabeling Methods.
    Dolovich MB
    J Aerosol Med Pulm Drug Deliv; 2022 Aug; 35(4):227-236. PubMed ID: 35834639
    [No Abstract]   [Full Text] [Related]  

  • 54. The effect of device resistance and inhalation flow rate on the lung deposition of orally inhaled mannitol dry powder.
    Yang MY; Verschuer J; Shi Y; Song Y; Katsifis A; Eberl S; Wong K; Brannan JD; Cai W; Finlay WH; Chan HK
    Int J Pharm; 2016 Nov; 513(1-2):294-301. PubMed ID: 27639621
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Air classifier technology (ACT) in dry powder inhalation Part 4. Performance of air classifier technology in the Novolizer multi-dose dry powder inhaler.
    de Boer AH; Hagedoorn P; Gjaltema D; Goede J; Frijlink HW
    Int J Pharm; 2006 Mar; 310(1-2):81-9. PubMed ID: 16442246
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Is the cellular uptake of respiratory aerosols delivered from different devices equivalent?
    Ong HX; Traini D; Loo CY; Sarkissian L; Lauretani G; Scalia S; Young PM
    Eur J Pharm Biopharm; 2015 Jun; 93():320-7. PubMed ID: 25930239
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparison of in vitro deposition of pharmaceutical aerosols in an idealized child throat with in vivo deposition in the upper respiratory tract of children.
    Ruzycki CA; Golshahi L; Vehring R; Finlay WH
    Pharm Res; 2014 Jun; 31(6):1525-35. PubMed ID: 24395403
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pharmacoscintigraphic evaluation of lipid dry powder budesonide formulations for inhalation.
    Sebti T; Pilcer G; Van Gansbeke B; Goldman S; Michils A; Vanderbist F; Amighi K
    Eur J Pharm Biopharm; 2006 Aug; 64(1):26-32. PubMed ID: 16697169
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A new Pharmaceutical Aerosol Deposition Device on Cell Cultures (PADDOCC) to evaluate pulmonary drug absorption for metered dose dry powder formulations.
    Hein S; Bur M; Schaefer UF; Lehr CM
    Eur J Pharm Biopharm; 2011 Jan; 77(1):132-8. PubMed ID: 20951200
    [TBL] [Abstract][Full Text] [Related]  

  • 60. In vitro dry powder inhaler formulation performance considerations.
    Ziffels S; Bemelmans NL; Durham PG; Hickey AJ
    J Control Release; 2015 Feb; 199():45-52. PubMed ID: 25497311
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.